Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report
Autor: | Katsuyoshi Tamaki, Akihiko Okubo |
---|---|
Rok vydání: | 2015 |
Předmět: |
Simeprevir
medicine.medical_specialty Time Factors Prednisolone viruses Case Report Antiviral Agents Gastroenterology Polyethylene Glycols Interstitial pneumonitis chemistry.chemical_compound Internal medicine Ribavirin Humans Medicine Adverse effect Glucocorticoids Aged Sulfonamides business.industry Interferon-alpha virus diseases General Medicine Hepatitis C Chronic biochemical phenomena metabolism and nutrition Virology Recombinant Proteins digestive system diseases Treatment Outcome chemistry Drug Therapy Combination Female Lung Diseases Interstitial Tomography X-Ray Computed business Heterocyclic Compounds 3-Ring |
Zdroj: | World Journal of Gastroenterology. 21:1009 |
ISSN: | 1007-9327 |
DOI: | 10.3748/wjg.v21.i3.1009 |
Popis: | The effectiveness of hepatitis C treatment has improved with the development of interferon (IFN), and it has drastically improved with the development of peg-interferon-α (PEG-IFN) in combination with ribavirin (RBV) and, more recently, with the addition of a protease inhibitor. Simeprevir, which is a second-generation protease inhibitor, has shown clinically favorable safety and tolerability profiles. Simeprevir received its first global approval in Japan in September 2013 for the treatment of genotype 1 chronic hepatitis C in combination with PEG-IFN and RBV. One serious adverse event associated with IFN therapy is interstitial pneumonitis, which can be fatal. We experienced a patient with interstitial pneumonitis that was induced by simeprevir with PEG-IFN and RBV therapy for chronic hepatitis C in the early stages of therapy (8 wk after initiating therapy). This is the first case report of interstitial pneumonitis with simeprevir with PEG-IFN and RBV in the world. In addition, it is very interesting that the onset of interstitial pneumonitis was earlier than that in conventional PEG-IFN and RBV therapy. This finding suggests that simeprevir augments the adverse event. We present this case report in light of relevant literature on interstitial pneumonitis with conventional PEG-IFN and RBV therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |